Johnson & Johnson Beats Q1 2026 Estimates Amid Stelara Patent Headwinds

Johnson & Johnson (NYSE: JNJ) has outperformed analyst expectations for the first quarter of 2026, providing a conservative boost to its full-year guidance. Despite the beat, the market response remained muted, with shares trading slightly lower following the announcement. The results highlight a transition period for the company as it balances the growth of new therapies against the loss of exclusivity for legacy blockbusters. While overall momentum has been strong over the past year—with shares rising over 52%—investors are now weighing valuation against patent cliffs. Growth was driven by strong performance in the oncology and immunology sectors. Darzalex, the company's blood cancer treatment, generated approximately $4 billion in sales, while Tremfya, used for psoriasis and inflammatory bowel disease, brought in $1.6 billion. However, the impact of patent expiration was evident in the performance of Stelara. Sales for the autoimmune treatment plummeted to $656 million in Q1 2026, down from $1.6 billion in the same period last year, as generic competition intensified. Looking ahead, JNJ remains a staple for stability seekers, boasting a 64-year streak of dividend increases. While the forward price-to-earnings ratio has climbed relative to recent quarters, the company's robust pipeline is expected to provide long-term upside.